Last quarter (Q ), Hoth Therapeutics's total revenue was $―, a decrease of ― from the same quarter last year. In Q, Hoth Therapeutics's net income was $-2.09M. See Hoth Therapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Total Revenue	$ 65.77M	$ 28.00K	$ 32.94K	$ 0.00	$ 0.00	$ 0.00
Cost of Revenue	$ 57.00K	-	-	-	-	-
Gross Profit	$ 65.74M	$ 28.00K	$ 32.94K	-	-	-
Operating Expense	$ -1.81M	$ 11.07M	$ 14.10M	$ 7.30M	$ 7.71M	$ 2.50M
Operating Income	$ -4.67M	$ -11.07M	$ -14.07M	$ -7.30M	$ -7.71M	$ -2.50M
Net Non Operating Interest Income Expense	$ 34.48K	$ 6.37K	-	-	$ 25.00	$ 0.00
Other Income Expense	$ 248.06K	$ 312.77K	$ 212.26K	$ 104.16K	$ 10.34K	-
Pretax Income	$ -4.27M	$ -5.89M	$ -14.28M	$ -7.20M	$ -7.70M	$ -2.50M
Tax Provision	$ -1.50M	$ 1.50M	$ 0.00	-	-	-
Earnings From Equity Interest Net Of Tax	$ -354.40K	$ -377.00K	-	-	-	-
Net Income Common Stockholders	$ -5.95M	$ -11.37M	$ -14.28M	$ -7.20M	$ -7.70M	$ -2.50M
Basic EPS	$ -9.30	$ -9.50	-	$ -0.58	$ -0.84	$ -0.26
Diluted EPS	$ -8.85	$ -8.79	$ -16.00	$ -0.58	$ -0.84	$ -0.26
Basic Average Shares	$ 10.47M	$ 1.20M	$ 893.20K	$ 12.36M	$ 9.16M	$ 9.42M
Diluted Average Shares	$ 10.47M	$ 1.20M	$ 894.61K	$ 12.36M	$ 9.16M	$ 9.42M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	$ 25.87K	$ 31.62K	$ 28.25K
Total Expenses	$ -1.76M	$ 11.07M	$ 14.10M	$ 7.30M	$ 7.71M	$ 2.50M
Net Income From Continuing And Discontinued Operation	$ -9.62M	$ -11.37M	$ -14.28M	$ -7.20M	$ -7.70M	$ -2.50M
Normalized Income	$ -1.81M	$ -4.31M	-	$ -7.20M	$ -7.71M	$ -2.50M
Interest Expense	-	-	-	-	-	$ 0.00
EBIT	$ -4.28M	$ -5.89M	$ -14.28M	$ -7.30M	$ -7.71M	$ -2.50M
EBITDA	$ -4.28M	$ -5.89M	$ -14.28M	$ -7.30M	$ -7.71M	$ -2.49M

Currency in USD

Hoth Therapeutics Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing